Parameter
| Biomarker | IgH transsituation (t (11;14)) | Full name | Immunoglobulin heavy chain translocation, reciprocal translocation between chromosome 11 and chromosome 14 | Molecular Type | nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis and Treatment Options | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow | Test Sample / Technology Platform | marrow | ||
| Pathobiological Mechanisms | t(11;14) induces overexpression of cyclin D1, resulting in a dormant disease state and sensitivity to BCL-2 inhibitors. | ||||
| Clinical Availability Status | clinical validation/trial application | ||||
| Notes and Dynamics | Patients with t(11;14) positivity who received venetoclax plus bortezomib achieved an overall response rate (ORR) of 78%–90%. Adverse infections should be noted, and the FDA has imposed restrictions on certain trials. | ||||